Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Join Prof. Jessica Lin as she explores key strategies for managing ALK+ NSCLC while prioritizing long-term patient safety

Speaker : Prof. Jessica Lin

Optimizing Treatment Options in Advanced Urothelial Carcinoma

Explore Dr. TamoJit Chaudhury’s expert insights on optimizing advanced urothelial carcinoma treatment, covering immunotherapy, targeted therapy, and clinical trial breakthroughs.

Speakers : Dr. Tamojit Chaudhury

Updates on the First Line Management of ALK+ NSCLC

In this webinar, a detailed discussion is done on Enhancing Outcomes in Advanced Lung Cancer

Speakers : Prof. Tony Mok

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Join Prof. Jessica Lin as she explores key strategies for managing ALK+ NSCLC while prioritizing long-term patient safety

Speakers : Prof. Jessica Lin

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

Join Prof. Solange Peters as she explores post-progression strategies after first-line third-generation ALK inhibitors in NSCLC.

Speakers : Prof. Solange Peters

Oropharyngeal Cancer in Relation to HPV Status

Learn about the occurrence of oropharyngeal cancer in HPV negative patients through different case presentations.

Speakers : Dr. Ashish M Kaushal

Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Dr. Rohit R Pai compares Nimotuzumab plus chemoradiotherapy vs. placebo plus chemoradiotherapy in locally advanced nasopharyngeal carcinoma (LA-NPC).

Speakers : Dr. Rohit R Pai - Speaker

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

Explore the role of Nimotuzumab in Nasopharyngeal Cancer management with Dr. Abhishek Raj, focusing on targeted therapy and improved patient outcomes.

Speakers : Dr. Abhishek Raj

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

Explore the benefits of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer with Dr. Shailesh Bondarde.

Speakers : Dr Shailesh Bondarde

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

Discover how CDK4/6 inhibitors extend progression-free survival (PFS) and overall survival (OS) in HR+/HER2- metastatic breast cancer (mBC) patients.

Speakers : Dr Parveen Jain

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

Explore expert insights on first-line maintenance therapy for metastatic urothelial carcinoma in this panel discussion featuring Dr. Tushar Patil, Dr. Varun Nagori, and Dr. Amol Dongre.

Speakers : Dr Tushar Patil ,Dr Varun Nagori ,Dr Amol Dongre


Recommended News For You

Coffee and tea linked to lower head and neck cancer risk

Telemedicine services linked to reducing excess mortality

Chemoradiation Plus Immunotherapy Fails to Improve Survival in Limited-Stage SCLC

Study finds that AI is better at forecasting the risk of developing cancer.

Since 2000, the outlook for multiple myeloma has improved.

Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.

Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy

Recommended Articles For You

Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options  

Understanding Drug-Induced Cardiotoxicity: Mechanisms, Impact, and Future Directions 

AI and Optical Advances: Evolving Blood Cell Morphology Observation in Hematology 

Unlocking the Potential of Reticulocytes: The Key to Enhanced Blood Production 
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Long Wait Times on the Other Side of the Pond: King Charles' Cancer Diagnosis.

2.

Chemo causes lasting physical decline in breast cancer survivors

3.

New study reveals racial disparities in breast cancer diagnosis and outcomes in Canada

4.

'Full House' Star's Cancer; Fluoride Fears Go Mainstream; Florida Doctor Arrested

5.

Recent Rise in Early-Onset Solid Tumors Is Associated with Accelerated Aging.

1.

Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors

2.

A Comprehensive Guide to Living with Cutaneous T Cell Lymphoma: Tips & Strategies 

3.

Living with Shwachman-Diamond Syndrome: A Journey of Hope and Strength

4.

RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health 

5.

Mitoxantrone–Napabucasin Co-Nanoformulation Activates cGAS-STING in HCC Therapy

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

3.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

4.

Updates on Standard V/S High Risk Myeloma Treatment- The Next Part

5.

An In-Depth Look At The Signs And Symptoms Of Lymphoma

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot